DS-103

DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin (HY-17394) resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis[1].

Product Specifications

UNSPSC

12352005

Target

HDAC; Parasite

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Smiles

O=C(N(CC1=CC=C(C=C1)C(NNCC)=O)CC(NCC2=CC=CC=C2)=O)C3=CC=C(C=C3)N(C)C

Molecular Formula

C28H33N5O3

Molecular Weight

487.59

References & Citations

[1]Stopper D, et al., Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 2025 Feb 27;68 (4) :4426-4452.